ORPHA:171695
Parkinsonian-pyramidal syndrome
Also known as: Pallidopyramidal syndrome
Publications
93
56.2th percentile
Trials
0
Interventional, condition-specific
Researchers
674
Distinct authors in sample
Gene link
FBXO7
Strong
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Parkinsonian-pyramidal syndrome is a rare, genetic, neurological disorder characterized by the association of both parkinsonian (i.e. bradykinesia, rigidity and/or rest tremor) and pyramidal (i.e. increased reflexes, extensor plantar reflexes, pyramidal weakness or spasticity) manifestations, which vary according to the underlying associated disease (e.g. neurodegenerative disease, inborn errors of metabolism).
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0009830
- MeSH:C538104
- OMIM:260300
- UMLS:C1850100
Additional Mondo synonyms (4)
Parkinson disease 15, autosomal recessive · autosomal recessive early-onset Parkinson disease type 15 · pallidopyramidal syndrome · parkinsonian-pyramidal syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Strong — FBXO7
- LiteraturePresent
93 matched papers (58 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (FBXO7).
GenCC classification: Strong.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
93
93 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
93 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
58 in the last 10 years · high confidence · 56.2th percentile (publications denominator)
Phrase hits: 93 · MeSH hits: 1
Who's working on it?
674
Distinct author names in 93 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Bonifati V6 papers · 2024
Erasmus MC, Department of Clinical Genetics, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
Papers in Europe PMC - 02Breedveld GJ5 papers · 2024
Institut du Cerveau et de la Moelle épinière, ICM, , , , ,
Papers in Europe PMC - 03Bhatia KP4 papers · 2025
Sobell Department of Motor Neuroscience and Movement Disorders Institute of Neurology University College London London United Kingdom.
Papers in Europe PMC - 04Di Fonzo A4 papers · 2024
IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit, Milan, Italy.
Papers in Europe PMC - 05Oostra BA4 papers · 2012Papers in Europe PMC
- 06Brice A3 papers · 2024
Sorbonne Université, UPMC Univ Paris 06, UM 1127, ICM, Paris, France; Inserm, U 1127, ICM, Paris, France; Cnrs, UMR 7225, ICM, Paris, France; ICM, Paris, F-75013, Paris, France.
Papers in Europe PMC - 07Houlden H3 papers · 2024
Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, UK. h.houlden@ucl.ac.uk.
Papers in Europe PMC - 08Joseph S3 papers · 2023
Department of Neurology, RWTH University Hospital, 52074 Aachen, Germany.
Papers in Europe PMC - 09Lesage S3 papers · 2024
Sorbonne Université, UPMC Univ Paris 06, UM 1127, ICM, Paris, France; Inserm, U 1127, ICM, Paris, France; Cnrs, UMR 7225, ICM, Paris, France; ICM, Paris, F-75013, Paris, France.
Papers in Europe PMC - 10Magrinelli F3 papers · 2025
Department of Clinical and Movement Neurosciences Queen Square London United Kingdom.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Parkinsonian-pyramidal syndrome" OR "Pallidopyramidal syndrome" OR "Parkinson disease 15, autosomal recessive" OR "autosomal recessive early-onset Parkinson disease type 15"
MeSH descriptor terms unioned into the query: Pallidopyramidal syndrome
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Parkinsonian-pyramidal syndrome" OR "Pallidopyramidal syndrome" OR "Parkinson disease 15, autosomal recessive" OR "autosomal recessive early-onset Parkinson disease type 15" OR "FBXO7" OR "parkinsonian disorder"
Recall-expansion terms: FBXO7, parkinsonian disorder
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T08:41:50.281Z